CD34 and acute myeloid leukemia: Despite the wide range of responses observed with patient-derived AML samples, normal human CD34-positive HSPCs were significantly more resistant to Dynole 34-2 (LC50: 23.03 ± 5.72 μM, Fig. 7b).